Cystic fibrosis (CF) therapy has traditionally been based on the treatment of symptoms and infections, rather than targeting the underlying defect caused by variants in the CFTRgene. Ivacaftor is the first FDA-approved drug to specifically target a particular defect of the CFTR protein. It is indicated for use in patients

CPIC has extensively reviewed the literature and concluded no changes are required to the therapeutic recommendations of the abacavir dosing guideline based on HLA-B genotype since the original publication in 2012. The 2014 update includes the following additions: * Clinical implementation resources to help implementation of the guidelines into an Electronic

In Current Drug Metabolism, the Clinical Pharmacogenetics Implementation Consortium (CPIC) has defined the standardized operating procedures undertaken for each guideline written. Outlined in the publication is how gene-drug relationships are initially assessed for a potential guideline, how a writing committee with experts in the subject is established, the gathering and

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published updates to the guidelines for the use of genetic test results for cytochrome P450-2D6 (CYP2D6) in codeine dosing. The 2014 update is now available online, as an accepted article preview.Alternate analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. Label recommended

The Genetics/Genomics Competency Center (G2C2) is a free, online resource that provides a collection of high quality educational materials for self-directed learning in genetics or genomics. It is targeted toward health care professionals such as genetic counselors, nurses, physician assistants and pharmacists. The educational information presented consists of journal